Oxidized LDL and other lipids as risk factors for cardiovascular disease in the patients with metabolic syndrom

Jugoslovenska Medicinska Biohemija

Volumn 24, Issue 2, 2005, Pages 99-106

  Zamaklar, Miroslava ^a,c   Lalić, Katarina ^a   Rajković, Nataša ^a   Trifunovic, Danijela ^b   Dragašević, Mirjana ^a   Popović, Ljiljana ^a   Drašković, Danijela ^a   Lalić, Nebojša ^a   Jotić, Aleksandra ^a   Lukić, Ljiljana ^a   Miličić, Tanja ^b   Potpara, Tanja ^b   Vasović, Olga ^a   Čolak, Emina ^c   Stojanović, Jecka ^c   Glišić, Biljana ^c  

^a Diabetes and Metabolic Disorders   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Antioxidative status; Coronary heart disease; Diabetes mellitus type 2; Lipids; oxLDL

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B100; APOLIPOPROTEIN E; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATION; OXIDATIVE STRESS; RISK FACTOR;

EID: 20244367605     PISSN: 03543447     EISSN: None     Source Type: Journal    
DOI: 10.2298/JMH0502099Z     Document Type: Article

References (26)

1. Reaven GM. The fourth musketeer-from Alexander Dumas to Cloude Bernard. Diabetologia 1995; 38: 3-13.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Med 1998; 15: 539-53.
3. Balkau B, Charles MA. Comment On the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabetic Med 1999; 16: 442-43.
4. Executive summary of the third report of the NCEP Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-59.
6. Group L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Clinical Practice 200; 113: 3-14.
7. Kraegen E, Cooney G, Ye Ji-Ming, Furler S. Peroxisome proliferator activated receptors, fatty acids and muscule insulin resistance. J R Soc Med 2002; 95 Suppl 42: 14-22.
8. Steals B. The clinical significance of the PPAR and agonism. Br J Diabetes Vasc Dis 2002; 2 Suppl 1: S28-S31.
9. Castelli W. Cholesterol and lipids in the risk of coronary artery disease. The Framingham Heart Study. Can J Cardiol 1988; 4 Suppl A: 5a-10a.
10. Assmann G, Cullen P, Schulte H. Simple scoring system for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) Study. Circulation 2002; 105: 310-15.
11. Taskinen MR. Diabetic dyslipidemia. Atherosclerosis 2002; Suppl 3: 47-51.
12. Betteridge J. Dyslipidaemia and diabetes-the clinical realities. Br J Cardiol 2004; 11, Suppl 2: S11-S15.
13. Haffner SM. Clinical Relevance of the Oxidative Stress Concept. Metabolism 2000; Supp 1: Vol 49: 30-4.
14. Steinberg D, Lewis A. Oxidative modification of LDL and Atherogenesis. Circulation 1997; 95 (4): 1062-72.
15. De Vinter MPJ, Van Dijk KW, Havekes LM, Hofker MH. Macrophage Scavenger Receptor Class A. Atheroscler Thromb Vasc Biol 2000; 88: 615-27.
16. Steinberg D. Low density lipoprotein oxidation and its pathological significance. J Biol Chem 1997; 272: 20963-66.
17. Goldstein S, Michel C, Borsa A, Saran M, Czapski G. A critical reelevation of some assay methods for superoxide dismuthase activity. Free Radical Biol Med 1988; 4: 295-303.
18. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of glutathione peroxidase. J Lab Clin Med 1967; 70: 158-63.
19. Miller NJ, Rice-Evance CA. Factors influencing the antioxidant activity determined by the ABTS + radical cation assay. Free Radic Res 1997; 26 (3): 195-9.
20. Lepšanović L, Lepšanović Lj. Dijagnostika hiperlipoproteinemija. In: Lepšanović L, Lešanović Lj eds. Klinička lipidologija. Beograd: Savremena administracija A.D, 2000: 59-69.
21. Boizel R, Benhamou PY, Lardy B et al. Ratio of triglycerides to HDL cholesterol is an indicator LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 2000; 23: 1679-85.
22. Third report of the National Cholesterol Education Program (NECEP). Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III), Final report. Circulation 2002; 106 (25): 3145-3421.
23. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocystein, lipoprotein (a) and standard cholesterol screening as predictors of periferal arterial disease. JAMA 2001; 285: 2481-85.
24. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
25. Skoglound-Andersson C, Tang R, Bond MG et al. LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. Arterioscler Thromb Vasc Biol 1999; 19: 2422-30.
26. Tan KCB, Ai VHG, Chow WS et al. Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and indipendent vasodilatation in patients with type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 3212-16.